Treating Alopecia

Expert Evaluation and Evidence-Based Management

More hair than usual in the shower drain. A widening part that was not there a year ago. A round, smooth patch on the scalp that appeared without warning. Noticing these changes is alarming. For many people, hair loss carries a weight that extends well beyond the physical, affecting identity, confidence, and how they move through the world each day. Understanding what is happening and having access to the right treatment can make a profound difference.

Alopecia is a broad medical term for any form of hair loss, encompassing more than a dozen distinct conditions that range from the gradual, genetically driven thinning of androgenetic alopecia to the sudden patchy loss of alopecia areata to the progressive, permanent scarring of frontal fibrosing alopecia. These conditions share the common outcome of hair loss but have fundamentally different causes, mechanisms, diagnostic features, and treatment requirements. The type of alopecia determines everything about how it should be managed, which is why accurate diagnosis is the essential foundation of effective hair loss care.

At Connolly Dermatology, we provide expert evaluation and alopecia treatment guided by evidence-based care. Our board-certified dermatologists use clinical examination, trichoscopy, scalp biopsy, and targeted laboratory testing to identify the specific type and cause of your hair loss, classify whether it is scarring or non-scarring, and design a treatment plan that reflects the latest evidence, including newly FDA-approved biologic therapies for alopecia areata. The goal is not only to slow or stop hair loss but, wherever the biology allows, to restore meaningful regrowth.

If you are experiencing hair loss of any kind, scheduling an evaluation with a dermatologist provides clarity. Have your scalp and hair assessed by the specialists at Connolly Dermatology and get the answers you need to move forward confidently.

Understanding Alopecia

Why the Type of Hair Loss Determines Every Aspect of Treatment

The most clinically important distinction in alopecia evaluation is between scarring and non-scarring forms of hair loss. In non-scarring alopecia, the hair follicle itself is preserved even when hairs are absent. The follicle retains its structural integrity and its capacity to produce hair, which means that effective treatment can restore growth. In scarring alopecia, also called cicatricial alopecia, the follicle is permanently destroyed and replaced by fibrous scar tissue. Hair loss in scarred areas is irreversible. The treatment goal shifts from restoration to halting progression and preserving the follicles that remain. Making this distinction early, before significant scarring has occurred, is one of the most time-sensitive aspects of hair loss evaluation and one of the clearest reasons why early dermatologic assessment matters.

Androgenetic Alopecia

Androgenetic alopecia, commonly called male pattern hair loss or female pattern hair loss, is the most common form of alopecia worldwide, affecting up to 50 percent of men by age 50 and up to 40 percent of women by age 70. It is a non-scarring condition driven by the interaction of genetic susceptibility with androgen hormones, specifically dihydrotestosterone (DHT), which is produced from testosterone by the enzyme 5-alpha reductase. In genetically susceptible follicles, DHT binds to androgen receptors and progressively miniaturizes the follicle through a process that shortens the anagen (growth) phase and produces progressively finer, shorter, and less pigmented hairs over successive cycles until the follicle becomes inactive. In men, the pattern follows the Hamilton-Norwood classification, beginning with recession at the temples and crown and progressing to variable degrees of baldness. In women, the Ludwig classification describes diffuse thinning with preservation of the frontal hairline, most prominent over the crown and part line. Because follicles are not destroyed in androgenetic alopecia, they remain capable of producing hair if the hormonal miniaturization signal is interrupted by effective treatment.

Alopecia Areata

Alopecia areata is an autoimmune condition in which autoreactive CD8+ T lymphocytes target hair follicles, abruptly arresting hair growth and causing rapid, patchy hair loss. The loss of immune privilege around the hair follicle bulb, which normally shields follicular antigens from immune recognition, is the central pathogenic event. The result is a characteristic oval or round patch of complete hair loss with smooth, entirely normal-appearing skin at the base. Alopecia areata affects approximately 2 percent of the global population across all ages, sexes, and ethnicities. In most cases, the patches are limited to one or a few areas of the scalp. In more severe forms, alopecia totalis involves complete scalp hair loss, and alopecia universalis extends hair loss to the entire body including eyebrows and eyelashes. Alopecia areata is non-scarring, meaning the follicles are preserved and capable of regrowth. The condition is associated with other autoimmune diseases including thyroid autoimmunity and vitiligo. The landmark approval of Janus kinase inhibitors, baricitinib in 2022 and ritlecitinib in 2023, by the FDA specifically for alopecia areata represents a transformative advance in treatment for patients with severe or refractory disease.

Telogen Effluvium

Telogen effluvium is a diffuse, non-scarring hair loss caused by a physiological disruption that prematurely shifts large numbers of actively growing (anagen) hairs into the resting (telogen) phase simultaneously. Two to three months after the triggering event, these hairs shed synchronously, producing the alarming diffuse shedding that brings most patients to evaluation. Common triggers include major illness or surgery, significant emotional or psychological stress, childbirth, rapid weight loss or crash dieting, nutritional deficiencies (particularly iron, ferritin, zinc, and protein), thyroid disease, and starting or stopping hormonal contraception. Telogen effluvium is among the most treatable forms of hair loss because it is typically self-limiting and reverses once the triggering cause is identified and addressed. The challenge is identifying the trigger from events that occurred months before the shedding began, which requires a detailed timeline history.

Frontal Fibrosing Alopecia

Frontal fibrosing alopecia is a scarring alopecia characterized by a slowly progressive recession of the frontal and temporal hairline, often accompanied by loss of eyebrows and eyelashes. It is considered a variant of lichen planopilaris and is driven by lymphocytic inflammation that destroys the follicular isthmus and bulge, producing irreversible follicular scarring. The receding band of skin at the hairline typically shows a pale, ivory discoloration and a band of perifollicular erythema and scale at the margin of active hair loss. Frontal fibrosing alopecia predominantly affects postmenopausal women, though it occurs in men and premenopausal women as well. Its incidence has increased significantly over recent decades, and research is ongoing into potential environmental and hormonal triggers. Because the hair loss is permanent in areas where scarring has occurred, early recognition and treatment to slow progression are essential.

Lichen Planopilaris

Lichen planopilaris is a primary lymphocytic cicatricial (scarring) alopecia that targets the follicular isthmus and stem cell niche, producing patchy, multifocal scarring hair loss predominantly on the vertex and parietal scalp. Active disease shows characteristic trichoscopic and clinical findings of perifollicular erythema and scale around individual follicular ostia, associated with itch, pain, or burning at the scalp. Progressive follicular destruction produces smooth, white atrophic patches where follicular openings are absent. Systemic anti-inflammatory and immunosuppressive therapies are required to achieve disease control and prevent continued follicular destruction.

Central Centrifugal Cicatricial Alopecia

Central centrifugal cicatricial alopecia (CCCA) is the most common form of scarring alopecia in Black women and is increasingly recognized in Black men as well. It begins at the vertex or crown of the scalp and expands centrifugally, producing a progressively enlarging zone of permanent hair loss surrounded by an advancing active margin. The underlying mechanism involves follicular inflammation and fibrosis of unclear origin, with genetic factors, chemical hair processing, and heat styling identified as potential contributors. Early CCCA may be subtle and asymptomatic, which is why the condition is frequently not identified until significant scarring has already occurred. Hair fragility, tenderness, and pustules may be present in the active zone.

Traction Alopecia

Traction alopecia develops when chronic mechanical tension applied to the hair follicle from tight hairstyles, including tight braids, cornrows, weaves, extensions, tight ponytails, and locs, exceeds the follicle’s structural tolerance. The resulting traction produces perifollicular inflammation and, with prolonged or repeated tension, progressive follicular miniaturization and eventual scarring. It most commonly presents as a band of thinning along the frontal and temporal hairline in the distribution of the tightest hair tension. Early traction alopecia is fully reversible when tension is eliminated. Advanced cases with established follicular scarring produce permanent hair loss that does not respond to tension modification alone.

Alopecia Types: Scarring vs. Non-Scarring Compared

The table below summarizes the key distinguishing features across the major alopecia subtypes. The scarring versus non-scarring classification determines reversibility and urgency of treatment.

These patterns represent typical presentations. Individual cases vary, and more than one type of alopecia can occur simultaneously. A board-certified dermatologist with trichoscopy expertise and access to scalp biopsy provides the definitive diagnosis.

Is Alopecia Medically Dangerous?

Most alopecia is not medically dangerous in a direct sense. It does not cause systemic illness and it does not become malignant. However, two important medical dimensions warrant serious attention.

First, alopecia is frequently the visible sign of an underlying systemic condition that does require treatment. Telogen effluvium can be the first sign of thyroid disease, iron deficiency, or significant nutritional deficiency. Alopecia areata is associated with autoimmune thyroid disease and other autoimmune conditions. Diffuse hair loss in women can indicate hormonal dysregulation, including polycystic ovary syndrome. Scarring alopecia can represent cutaneous lupus erythematosus affecting the scalp, which requires evaluation for systemic lupus. Identifying the alopecia correctly is not only about hair; it is sometimes about finding systemic disease that needs treatment.

Second, scarring forms of alopecia produce permanent hair loss that progresses until inflammation is suppressed. A delay of months or years between symptom onset and treatment initiation translates directly into irreversible follicular loss that could have been prevented. For patients with frontal fibrosing alopecia, lichen planopilaris, or central centrifugal cicatricial alopecia, the time between first symptom and first dermatology visit has a direct and lasting impact on outcome. The documented psychological burden of alopecia is also clinically significant: published research consistently demonstrates high rates of depression, anxiety, and substantially reduced quality of life in patients with significant hair loss, comparable in impact to other chronic dermatologic and medical conditions.

Signs and Symptoms of Alopecia

Alopecia presents differently depending on the type, and recognizing the specific features of your hair loss helps direct a more efficient and accurate evaluation. The following features are what your dermatologist assesses systematically during a hair loss evaluation.

Pattern of Hair Loss

The distribution of hair loss across the scalp and body is the single most diagnostically informative feature. A receding frontal hairline with thinning at the crown in a male-pattern distribution points immediately toward androgenetic alopecia. Diffuse thinning with widening of the part and reduced volume across the crown in a woman with preserved frontal hairline suggests female pattern hair loss. Round or oval smooth bald patches with abrupt borders and entirely normal-appearing scalp skin are the hallmark of alopecia areata. Progressive recession of the frontal hairline as a band, accompanied by eyebrow loss, is characteristic of frontal fibrosing alopecia. Vertex-centered expansion of smooth, shiny scalp loss points toward central centrifugal cicatricial alopecia. A band of thinning along the temporal and frontal hairline in the distribution of tight hairstyle tension identifies traction alopecia. Each pattern tells a diagnostic story that guides the evaluation efficiently.

Rate of Progression

How quickly hair loss is progressing provides important diagnostic and prognostic information. Rapid, dramatic shedding over days to weeks, filling the hairbrush and shower drain, is characteristic of telogen effluvium and acute alopecia areata. Slow, gradual thinning over years is consistent with androgenetic alopecia. Steady, progressive recession of the hairline over months to years suggests frontal fibrosing alopecia. Sudden onset of a completely bald patch that was not present weeks earlier is a hallmark presentation of alopecia areata that prompts urgent evaluation.

Scalp Symptoms

The presence or absence of scalp symptoms narrows the differential diagnosis significantly. Androgenetic alopecia and most cases of telogen effluvium produce no scalp symptoms whatsoever. The scalp looks and feels entirely normal. Alopecia areata may produce tingling or mild discomfort at the edges of active patches. Active lichen planopilaris and frontal fibrosing alopecia frequently produce scalp itch, burning, pain, or tenderness at the sites of active follicular inflammation, which are important symptoms that confirm active disease requiring treatment. Central centrifugal cicatricial alopecia can be completely asymptomatic in early stages, making it easily missed, or may produce scalp tenderness in the vertex area. Pustules on the scalp may accompany active CCCA or folliculitis decalvans, another scarring condition.

Hair Shaft Characteristics

The caliber, length, and fragility of the remaining hairs in the affected area carry diagnostic information visible on trichoscopy and physical examination. Miniaturized, fine, short vellus hairs in the crown area are pathognomonic of androgenetic alopecia at the trichoscopic level. Broken hairs of irregular length, “exclamation mark” hairs that taper at their base, and black dots representing broken hairs at the follicular opening are trichoscopic signatures of alopecia areata. Hair fragility and easy breakage at the scalp level in the vertex area raise the possibility of traction damage or CCCA. Complete absence of any hair, even vellus hair, in a smooth, ivory patch at the hairline confirms established scarring in frontal fibrosing alopecia.

Nail and Body Hair Changes

Alopecia areata frequently involves structures beyond the scalp. Nail pitting, a regular array of small depressions across the nail surface, is present in 10 to 20 percent of patients with alopecia areata and can be an early diagnostic clue even when scalp findings are subtle. Eyebrow and eyelash loss accompany alopecia areata in a significant proportion of patients and are defining features of frontal fibrosing alopecia. Loss of body hair including axillary, pubic, and limb hair occurs in alopecia universalis. These extra-scalp findings are examined systematically during a comprehensive hair loss evaluation.

Signs That Warrant Prompt Evaluation

You should see a dermatologist promptly for hair loss evaluation if you notice:

•         Sudden onset of one or more smooth, round bald patches on the scalp
•         Rapidly progressive hair loss occurring over days to weeks
•         Scalp itch, burning, pain, or tenderness in areas of hair loss
•         Progressive recession of the frontal or temporal hairline
•         Expanding smooth, shiny baldness at the crown of the scalp
•         Hair loss accompanied by systemic symptoms including fatigue, weight change, heat or cold intolerance, or menstrual irregularity
•         Hair loss alongside eyebrow or eyelash thinning or loss
•         Patchy hair loss with scalp scaling, pustules, or scarring
•         Hair loss causing significant psychological distress, regardless of its rate of progression

Early evaluation is particularly important for suspected scarring alopecia, where each month of treatment delay corresponds directly to follicular loss that cannot be reversed.

Risk Factors for Alopecia

The risk factors for hair loss differ significantly across alopecia types. Understanding what raises your risk of specific conditions helps contextualize your evaluation and guides the diagnostic workup your dermatologist orders.

Genetics and Family History

Androgenetic alopecia has a strong polygenic genetic basis. A family history of pattern hair loss on either the maternal or paternal side substantially increases personal risk. The condition is not exclusively inherited from the maternal grandfather, as the popular myth suggests; multiple genetic loci on different chromosomes contribute, and the inheritance is complex. Alopecia areata also has a significant genetic component; having a first-degree relative with alopecia areata approximately doubles the risk, and twin studies confirm a substantial genetic contribution to susceptibility. Frontal fibrosing alopecia and lichen planopilaris appear to have genetic predispositions that are currently under active investigation. CCCA has a documented genetic component, with variants in the PAD13 gene encoding an enzyme involved in hair shaft integrity identified in a proportion of affected individuals.

Hormonal Factors

Androgens are central to androgenetic alopecia in both men and women. While most women with female pattern hair loss have normal serum androgen levels, their follicles are more sensitive to the miniaturizing effects of DHT due to genetic androgen receptor variation. In some women, elevated androgens from polycystic ovary syndrome, congenital adrenal hyperplasia, or androgen-secreting tumors drive or accelerate hair loss. This subset requires hormonal evaluation to identify the systemic cause. Hormonal transitions, including postpartum estrogen withdrawal, menopause-associated estrogen decline, and changes related to hormonal contraception initiation or discontinuation, can precipitate telogen effluvium or worsen androgenetic alopecia by altering the hormonal balance that modulates follicular cycling.

Autoimmune Conditions

A personal or family history of autoimmune thyroid disease (Hashimoto thyroiditis or Graves disease), vitiligo, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, or other autoimmune conditions significantly elevates the risk of developing alopecia areata. The shared immunological dysregulation that underlies these conditions also lowers the threshold for autoimmune targeting of hair follicles. Patients with alopecia areata have thyroid autoantibodies at elevated rates and warrant thyroid screening.

Nutritional Deficiencies

Nutritional deficiencies are a direct and treatable cause of telogen effluvium and an exacerbating factor in other alopecia types. Iron deficiency, even in the absence of frank anemia, is consistently associated with increased hair shedding. Serum ferritin, not just hemoglobin, is the appropriate screening parameter; ferritin levels below 30 to 70 ng/mL have been associated with telogen effluvium in multiple studies. Zinc deficiency impairs hair matrix cell proliferation and produces hair fragility and loss. Protein deficiency from crash dieting, eating disorders, or severe illness deprives the rapidly dividing hair matrix cells of essential building materials. Vitamin D deficiency has been associated with alopecia areata and may contribute to androgenetic alopecia in some patients. Biotin deficiency produces hair loss but is far rarer than biotin supplement marketing suggests; most patients consuming a standard diet do not benefit from biotin supplementation for hair loss.

Medications

Medications are a frequently overlooked cause of hair loss. Chemotherapy agents produce the predictable, well-known anagen effluvium affecting actively dividing hair matrix cells. However, many commonly used medications produce telogen effluvium that is temporally delayed from initiation, making the causal relationship non-obvious. Anticoagulants (heparin, warfarin), retinoids, antihypertensives (beta-blockers, ACE inhibitors), antidepressants, mood stabilizers (lithium, valproate), hormonal contraceptives (particularly progestin-dominant preparations), and certain immunosuppressive agents are among the most frequently implicated drugs. A complete medication review including recently started or stopped agents is an essential component of the hair loss evaluation.

Hairstyling Practices

Chronic mechanical tension from tight braids, cornrows, weaves, extensions, tight buns, locs, and tight ponytails is the direct cause of traction alopecia. Chemical processing with relaxers, bleach, and permanent wave solutions, combined with heat styling, weakens the hair shaft and may contribute to CCCA in susceptible individuals. Dermatologic counseling on safe hairstyling practices is a clinically important component of CCCA management and traction alopecia prevention.

Can Alopecia Be Prevented?

Prevention depends on the type of alopecia. Androgenetic alopecia cannot be fully prevented when genetic predisposition is present, but its progression can be substantially slowed with early treatment. For conditions where identifiable and modifiable contributing factors exist, early action reduces progression risk meaningfully.

Start Treatment Early for Androgenetic Alopecia

The hair follicles that produce androgenetic alopecia undergo progressive miniaturization over years. Early intervention with minoxidil and 5-alpha reductase inhibitors significantly slows this progression and, in many patients, reverses miniaturization in follicles that have not yet become dormant. Waiting until hair loss is visually dramatic means that many follicles have already progressed beyond the point where they respond to treatment. Earlier is better in every clinical scenario for androgenetic alopecia.

Protect Against Scalp Inflammation in Scarring Alopecia

For patients diagnosed with lichen planopilaris, frontal fibrosing alopecia, or CCCA, anti-inflammatory treatment initiated while active disease is present suppresses follicular destruction and preserves follicles that would otherwise be permanently lost. Consistent maintenance therapy during periods of apparent quiescence reduces the frequency and severity of recurrent inflammatory activity.

Address Nutritional Deficiencies

Correcting identified iron, zinc, protein, and vitamin D deficiencies through diet and supplementation reduces the burden on follicular cycling and can reverse telogen effluvium-associated shedding within 3 to 6 months of repletion.

Modify Hairstyling Practices

Eliminating chronic scalp tension by transitioning away from tight hairstyles, reducing chemical processing frequency, and incorporating low-tension styling alternatives reverses early traction alopecia and slows CCCA progression in patients where these factors are contributing.

Diagnosis and Evaluation of Alopecia

Accurate diagnosis of alopecia requires a structured, multi-modal evaluation that goes substantially beyond a visual inspection of the scalp. The type of alopecia, whether it is scarring or non-scarring, the degree of disease activity, the presence of contributing systemic factors, and the most appropriate treatment sequence all depend on a correct diagnosis. At Connolly Dermatology, we use a comprehensive diagnostic approach that assembles clinical history, physical examination, trichoscopy, targeted laboratory workup, and scalp biopsy when indicated into a specific, actionable diagnostic conclusion.

Clinical History

The hair loss history is the starting point of every evaluation. Your dermatologist documents when hair loss began, how it has progressed, whether it is generalized or localized, and which areas of the scalp and body are affected. Accompanying scalp symptoms including itch, burning, and pain identify active inflammatory disease. Medication history with a specific focus on agents started in the preceding 3 to 6 months is reviewed thoroughly. Recent significant life events, illnesses, surgeries, dietary changes, or periods of severe stress are explored as potential telogen effluvium triggers. Obstetric and gynecologic history is documented in women. Family history of alopecia and personal and family history of autoimmune conditions are assessed. Current hairstyling practices including frequency of chemical processing, heat styling, and any history of tight tension hairstyles are reviewed.

Physical Examination and Hair Pull Test

A complete hair and scalp examination is conducted across the full scalp surface. The density, diameter, and distribution of remaining hairs are assessed. The frontal hairline, temporal areas, crown, vertex, and occiput are each evaluated. Eyebrows, eyelashes, and body hair are examined when clinically relevant. The hair pull test, which involves grasping approximately 60 hairs between the thumb and index finger and applying smooth traction, provides immediate bedside information about active shedding. A yield of more than six hairs from a single pull is considered positive and indicates active effluvium. Nail examination for pitting, leukonychia, or other nail changes associated with alopecia areata is performed.

Trichoscopy (Dermoscopy of the Scalp)

Trichoscopy is dermoscopy applied to the scalp and hair, providing magnified visualization of follicular architecture, hair shaft characteristics, and scalp surface features that are invisible to the naked eye. It is one of the most powerful non-invasive diagnostic tools in alopecia evaluation and, in experienced hands, frequently produces a diagnosis without the need for biopsy. The trichoscopic findings are highly specific to individual alopecia types. In androgenetic alopecia, a ratio of miniaturized vellus to terminal hairs exceeding 20 percent and a peripilar brown halo sign confirm the diagnosis. In alopecia areata, exclamation mark hairs, yellow dots representing empty follicular infundibula filled with sebum, black dots representing broken hairs at the follicular opening, and cadaver hairs identify active disease. Perifollicular tubular scale and absent follicular openings in the scarred zone are the hallmark trichoscopic findings of lichen planopilaris and frontal fibrosing alopecia. Hyperpigmented halos around follicular units at the vertex are characteristic of early CCCA.

Scalp Biopsy

Scalp biopsy is the gold standard for diagnosing scarring alopecia, for distinguishing between forms of scarring alopecia that share clinical features, and for confirming alopecia diagnoses in clinically ambiguous cases. Two 4-millimeter punch biopsies are typically obtained: one processed with horizontal sectioning to assess follicular density, miniaturization ratio, and fibrotic track counts, and one with vertical sectioning to visualize the follicular architecture and inflammatory infiltrate pattern. The histopathologic pattern identifies the specific type of scarring alopecia, distinguishes between lymphocytic and neutrophilic forms, and confirms the presence or absence of fibrotic replacement. Biopsy is performed under local anesthesia in the office and produces a small wound that heals within one to two weeks. In alopecia areata with uncertain trichoscopic findings, biopsy confirms the characteristic peribulbar lymphocytic infiltrate called “swarm of bees” pattern.

Targeted Laboratory Studies

Laboratory investigations for alopecia are directed by the clinical picture. For patients presenting with diffuse shedding consistent with telogen effluvium, a complete blood count, comprehensive metabolic panel, thyroid-stimulating hormone, serum ferritin, iron and total iron-binding capacity, zinc, and vitamin D 25-OH levels are ordered to identify correctable nutritional and systemic contributors. In women with androgenetic alopecia, particularly those with signs of hyperandrogenism, free and total testosterone, DHEA-S, and prolactin are measured. In alopecia areata, thyroid function tests and thyroid autoantibody levels are routinely obtained. In patients with suspected systemic autoimmune disease associated with scarring alopecia, antinuclear antibody, anti-double-stranded DNA, and complement levels are included. Targeted testing produces actionable information; unfocused, comprehensive panels without clinical indication add cost and confusion without improving diagnostic clarity.

When Should You Get Alopecia Evaluated?

You should see a dermatologist if you notice:

•         Any new patchy or diffuse hair loss that was not present six months ago
•         Progressive recession of the frontal or temporal hairline at any rate of change
•         Expanding baldness at the crown or vertex of the scalp
•         Scalp itch, burning, tenderness, or pain in areas where hair loss is occurring
•         Hair loss accompanied by fatigue, weight change, menstrual irregularity, or other systemic symptoms
•         Hair loss alongside eyebrow, eyelash, or body hair loss
•         Hair loss that has not responded to over-the-counter minoxidil after 6 months of consistent use
•         Hair loss causing significant psychological distress or affecting daily quality of life
•         Any hair loss that concerns you, regardless of whether it seems rapid or gradual

For scarring alopecias in particular, earlier evaluation is not merely preferable but critical. Every month of active inflammation translates into permanent follicular loss. The sooner treatment is initiated, the more hair is preserved.

Alopecia Treatment Options

Alopecia treatment is highly type-specific. The interventions used for androgenetic alopecia are not effective for alopecia areata. The treatments required for scarring alopecia differ fundamentally from those used for telogen effluvium. Once a specific diagnosis is established, treatment is selected based on the alopecia type, disease severity, the reversibility of existing hair loss, and the patient’s goals. The following represents the evidence-based treatment landscape across the major alopecia types managed at Connolly Dermatology.

Androgenetic Alopecia: DHT Suppression and Follicular Stimulation

Minoxidil

Topical minoxidil is the most widely used and consistently evidence-supported pharmacological treatment for androgenetic alopecia in both men and women. Available as a 2% solution or foam (FDA-approved for women) and 5% solution or foam (FDA-approved for men and used off-label in women at the same dosing), minoxidil prolongs the anagen growth phase, increases follicular size, and enhances blood flow to the follicular dermal papilla. Applied once or twice daily to the scalp, it reduces shedding within the first several months and produces visible regrowth in the majority of consistent users over 6 to 12 months. The primary limitation is that benefits are sustained only with continued use; discontinuation results in return to the pre-treatment hair loss trajectory within 3 to 6 months. Oral minoxidil at low doses (0.625 to 2.5 mg daily in women; 2.5 to 5 mg daily in men) is increasingly used off-label and offers systemic dosing that benefits all follicles simultaneously; research supports its efficacy and tolerability at these low doses compared to traditional topical application.

Finasteride and Dutasteride

Finasteride 1 mg daily is an oral 5-alpha reductase type II inhibitor FDA-approved for male androgenetic alopecia. It reduces scalp DHT levels by approximately 60 percent, slowing follicular miniaturization and producing measurable regrowth in the majority of treated men over 12 to 24 months of consistent use. Dutasteride 0.5 mg daily inhibits both type I and type II 5-alpha reductase, reducing scalp DHT by approximately 90 percent, and is more potent than finasteride, producing superior hair counts in clinical trials. Both agents are used off-label in women who are not pregnant or planning pregnancy, particularly those with elevated androgens or androgenetic alopecia refractory to minoxidil alone. They are used with careful counseling about the teratogenic risk in pregnant women and the small risk of persistent sexual side effects in a subset of men.

Spironolactone

Spironolactone, an oral aldosterone antagonist with anti-androgenic properties, is widely used off-label for female pattern hair loss, particularly in women with elevated androgens or clinical signs of hyperandrogenism. At doses of 50 to 200 mg daily, it blocks androgen receptor binding at the follicular level and reduces adrenal androgen production, attenuating the DHT-mediated miniaturization signal. It is the most commonly prescribed systemic agent for female androgenetic alopecia in the United States and produces meaningful improvement in hair density in a majority of treated women.

Platelet-Rich Plasma Therapy

Platelet-rich plasma (PRP) is prepared from the patient’s own blood by centrifugation and injected into the scalp at follicular sites. The concentrated growth factors released by activated platelets, including platelet-derived growth factor, vascular endothelial growth factor, and insulin-like growth factor, stimulate follicular proliferation, angiogenesis, and hair shaft elongation. Multiple clinical trials and systematic reviews support PRP injections as an effective adjunctive treatment for androgenetic alopecia and alopecia areata. Treatment typically involves three to four monthly sessions followed by maintenance injections every 3 to 6 months. PRP is well-tolerated, uses the patient’s own biological material, and complements pharmacological management.

Low-Level Laser Therapy

Low-level laser therapy devices, including FDA-cleared laser combs, helmets, and in-office systems, deliver red and near-infrared light to scalp tissue. Photobiomodulation through these wavelengths is believed to enhance mitochondrial function and cellular energy production in follicular cells, promoting anagen phase prolongation and reducing inflammation. Multiple randomized controlled trials demonstrate statistically significant increases in hair count with consistent use. Low-level laser therapy is most effective as an adjunct to pharmacological treatment in androgenetic alopecia rather than as monotherapy.

Alopecia Areata: Immunosuppression and JAK Inhibitor Therapy

Intralesional Corticosteroids

Intralesional triamcinolone acetonide injected directly into bald patches is the most widely used and consistently effective first-line treatment for limited alopecia areata. Injections of triamcinolone acetonide at 5 to 10 mg/mL are administered at 1-centimeter intervals across the bald patch every 4 to 6 weeks. Visible regrowth typically begins within 6 to 12 weeks of the first injection. This approach is most effective for patchy disease limited to fewer than three to five patches and for maintaining regrowth in localized disease. It is not practical for alopecia totalis or universalis affecting large body surface areas.

JAK Inhibitors: Baricitinib and Ritlecitinib

The FDA approval of baricitinib (Olumiant) in June 2022 and ritlecitinib (Litfulo) in June 2023 for severe alopecia areata in adults and adolescents respectively represents the most significant therapeutic advance in alopecia areata treatment in decades. Both agents are oral Janus kinase inhibitors that suppress the JAK-STAT signaling pathway through which interferon-gamma-driven T-cell cytokine signaling maintains the autoimmune attack on hair follicles. Baricitinib 4 mg daily and ritlecitinib 50 mg daily produce scalp hair coverage of 80 percent or more in approximately 35 to 40 percent of treated patients in pivotal clinical trials, with meaningful regrowth in a larger proportion. Treatment must be continued to maintain benefit; most patients experience re-loss after discontinuation. These agents are indicated for severe alopecia areata, defined as 50 percent or more scalp involvement, and for patients who have not achieved adequate response to intralesional corticosteroids or topical immunotherapy. They require baseline and periodic laboratory monitoring including complete blood count, lipid panel, and renal function.

Topical and Systemic Corticosteroids

Topical high-potency corticosteroids applied daily to bald patches are a first-line option for children with alopecia areata, for adults who prefer topical therapy, and as adjunctive treatment alongside intralesional injections. Short courses of oral prednisone can arrest rapidly progressive alopecia areata and stimulate regrowth but are not appropriate for long-term management due to systemic side effects. They are most useful as a bridging strategy while initiating sustained immunosuppressive treatment.

Contact Immunotherapy (DPCP)

Topical sensitization with diphenylcyclopropenone (DPCP) or squaric acid dibutyl ester (SADBE) is an established treatment for extensive, treatment-refractory alopecia areata. Patients are first sensitized with a high concentration of the agent, then treated with progressively lower concentrations weekly to maintain a mild controlled allergic contact dermatitis on the scalp. The resulting immune modulation alters the local T-cell environment in a way that reduces autoimmune follicular targeting. Response rates are meaningful in a proportion of refractory patients. This treatment is available in specialized dermatology practices with experience in this technique.

Scarring Alopecia: Anti-Inflammatory Therapy and Follicular Preservation

All scarring alopecia types share a common treatment priority: halting active inflammation before additional follicles are permanently destroyed. The specific agents used depend on whether the infiltrate is lymphocytic (lichen planopilaris, frontal fibrosing alopecia, discoid lupus) or neutrophilic (folliculitis decalvans, dissecting cellulitis).

Lichen Planopilaris and Frontal Fibrosing Alopecia: High-potency topical corticosteroids and intralesional triamcinolone are used at the active inflammatory margin to suppress localized inflammation. Hydroxychloroquine at 200 to 400 mg daily is the most widely used systemic agent, with an evidence base supporting its anti-inflammatory effect in both conditions over 6 to 24 months of treatment. 5-Alpha reductase inhibitors (finasteride or dutasteride) are used in frontal fibrosing alopecia based on observational data supporting their role in slowing hairline recession. For more active or refractory disease, mycophenolate mofetil, cyclosporine, or pioglitazone are used as second-line systemic agents. Strict photoprotection is recommended for frontal fibrosing alopecia patients, as UV exposure has been suggested as a contributing environmental factor.

Central Centrifugal Cicatricial Alopecia: Treatment combines topical and intralesional corticosteroids to suppress active scalp inflammation with elimination of chemical processing, heat styling, and tight hairstyle tension that may be contributing. Oral tetracycline-class antibiotics are used for their anti-inflammatory properties when inflammatory activity is significant. Minoxidil is added to stimulate remaining follicles at the active margin. Patient education on hair care modification is an integral component of CCCA management.

Telogen Effluvium: Trigger Identification and Correction

Telogen effluvium management centers on identifying and addressing the triggering cause. Identified nutritional deficiencies are corrected through dietary modification and targeted supplementation. Thyroid disease is treated in coordination with endocrinology. Implicated medications are discontinued or substituted in consultation with prescribing physicians when clinically appropriate. Topical minoxidil is used during the recovery phase to support follicular re-entry into anagen and reduce the shedding period. Most patients with acute telogen effluvium see significant shedding reduction within 3 to 6 months of trigger resolution and return to baseline hair density within 6 to 12 months.

Hair Transplantation

Surgical hair transplantation is a definitive option for stable androgenetic alopecia in appropriate candidates. Follicular unit extraction and follicular unit transplantation techniques harvest follicles from the permanent, DHT-resistant occipital donor zone and relocate them to thinning or bald recipient areas. Because transplanted follicles retain the genetic characteristics of their origin site, they are resistant to future androgenetic miniaturization. Hair transplantation is most successful in patients with stable disease who have optimized medical management to slow progression in non-transplanted areas. It is not appropriate for active scarring alopecia, active alopecia areata, or traction alopecia without hairstyle modification, as ongoing follicular destruction in the recipient area will affect transplanted grafts.

Why Choose Connolly Dermatology for Alopecia Treatment

Care Guided by Experience and Clinical Judgment

Hair loss is one of the most emotionally significant conditions a dermatologist evaluates. Patients frequently arrive after months or years of watching their hair change, trying over-the-counter treatments that did not work, or being told the cause was stress without a specific diagnosis or plan. Connolly Dermatology provides the systematic, clinically rigorous evaluation that alopecia demands, with access to the full spectrum of evidence-based treatments from established topical therapies through the newest FDA-approved biologics for alopecia areata.

Board-Certified Dermatologists

Our dermatologists are trained in the complete evaluation and management of alopecia across all types and all stages, from the earliest presentations of androgenetic alopecia through complex scarring conditions requiring systemic anti-inflammatory therapy. Every treatment recommendation reflects current clinical guidelines and the strongest available evidence.

Trichoscopy and Advanced Scalp Diagnosis

We perform trichoscopy at every hair loss evaluation, providing magnified visualization of follicular architecture that is unavailable with the naked eye. Trichoscopic findings frequently allow confident non-invasive diagnosis or narrow the differential to the point where targeted biopsy selection and panel laboratory testing become significantly more efficient and informative.

Access to JAK Inhibitor Therapy for Alopecia Areata

For patients with severe or refractory alopecia areata, we offer FDA-approved JAK inhibitor therapy with baricitinib and ritlecitinib, the most effective treatments available for this condition. Patients who have experienced years of incomplete regrowth from intralesional steroids and topical therapy deserve access to these transformative therapies, and we have the clinical infrastructure to prescribe, monitor, and manage them safely.

Scalp Biopsy When Scarring Cannot Be Excluded

We perform in-office scalp biopsies when trichoscopic findings do not conclusively distinguish between alopecia types or when scarring cannot be excluded on clinical grounds. For all patients with suspected scarring alopecia, biopsy is performed promptly because the diagnostic and treatment urgency is greatest in this population. Results are processed with appropriate horizontal and vertical sectioning and reviewed by dermatopathologists experienced in hair pathology.

Platelet-Rich Plasma Therapy

We offer in-office PRP therapy as an adjunctive treatment for androgenetic alopecia and alopecia areata, using the patient’s own platelet-derived growth factors to enhance follicular stimulation alongside pharmacological management. PRP is integrated into individualized treatment plans based on diagnosis, disease severity, and patient goals.

Honest Communication About Outcomes

We tell every patient clearly what type of alopecia they have, what the realistic expectations for treatment are, and whether the hair loss they have already experienced is reversible. For scarring alopecia, we explain honestly that previously scarred areas will not regenerate but that active treatment can preserve what remains. For androgenetic alopecia and alopecia areata, we set clear timelines for expected response and explain the maintenance commitments required to sustain benefit.

Compassionate, Patient-Centered Care

Hair loss affects identity and self-perception in ways that deserve to be taken seriously, not minimized. Every hair loss consultation at Connolly Dermatology includes dedicated time for the patient to describe their experience, ask their questions, and understand their diagnosis and plan in full. We want you to leave every appointment with a clear understanding of your condition and confidence in the path forward.

What To Expect During Treatment

Guiding You Through Evaluation and the Next Steps

Hair loss evaluation can feel uncertain and emotionally charged, particularly after months of watching changes without a clear explanation. At Connolly Dermatology, every stage of the process is structured so that you understand what is being assessed, why it matters, and what comes next.

Before Your Appointment

Preparing before your visit significantly improves your evaluation. Document when you first noticed hair changes, which areas are affected, whether shedding has increased, and how rapidly the changes have progressed. Photograph affected scalp areas with good lighting, including the part line, temples, crown, and hairline, to provide a baseline record and capture features that may not be visible on the day of the appointment. Note all current medications and any started or stopped in the preceding 6 months. Record recent significant events including illnesses, surgeries, childbirth, significant weight changes, or periods of major psychological stress that occurred 2 to 4 months before shedding increased. Document your current and recent hairstyling practices, including chemical processing, heat styling, and any history of tension hairstyles. Write down your personal and family medical history including any autoimmune conditions, thyroid disease, and family history of hair loss. Bring a list of all supplements and vitamins you currently take.

During the Evaluation

Your dermatologist reviews your history in detail before examining the scalp and hair. The hair pull test is performed. Trichoscopy is applied to affected and unaffected scalp regions. If scalp biopsy is indicated, the procedure is explained before it is performed. It is done under local anesthesia, takes less than 15 minutes, and produces a small wound that heals within one to two weeks.

Your dermatologist explains the diagnosis, what caused it, how it is expected to progress without treatment, what treatment options are available, and what realistic outcomes to expect over the treatment timeline. For androgenetic alopecia, the sustained nature of treatment and the timeline to visible response are discussed explicitly. For scarring alopecia, the urgency of treatment initiation and the goal of preservation rather than reversal of existing loss are clearly communicated. For alopecia areata, the full treatment spectrum, from topical and intralesional approaches through JAK inhibitor therapy for severe disease, is presented based on your disease severity.

After Your First Visit

Treatment is initiated based on your specific diagnosis and disease severity. For androgenetic alopecia, most patients begin a combination of topical or oral minoxidil and, where appropriate, hormonal therapy. Visible response is assessed at 3 to 6 months. For alopecia areata treated with intralesional corticosteroids, the first signs of regrowth are typically visible within 6 to 12 weeks. For patients initiating JAK inhibitor therapy, laboratory baseline tests are completed before prescriptions are filled, and monitoring is structured at defined intervals. For scarring alopecia, the first follow-up visit is typically scheduled within 2 to 3 months to assess treatment response and inflammatory activity.

Treatment response is documented at each visit with clinical photographs and trichoscopic comparison. Treatment plans are adjusted based on documented response, tolerability, and disease activity. Patients who have been struggling with hair loss without a clear answer or effective treatment for months or years consistently report that structured dermatologic evaluation and a personalized, diagnosis-specific treatment plan make a meaningful difference in both their clinical outcomes and their sense of control over their condition.

Get Clear Answers from Connolly Dermatology

Make Informed Decisions About Your Hair and Scalp Health

Alopecia encompasses a broad spectrum of distinct conditions, from the gradual androgen-driven miniaturization of androgenetic alopecia and the autoimmune follicular arrest of alopecia areata to the permanently destructive inflammation of frontal fibrosing alopecia and lichen planopilaris. Each type has a different cause, a different prognosis, and a different treatment approach. What they share is that early, accurate diagnosis and evidence-based treatment produce significantly better outcomes than delayed evaluation or non-specific symptomatic management.

For non-scarring conditions, effective treatment slows progression, reverses existing miniaturization, and restores meaningful density when initiated early. For scarring conditions, prompt anti-inflammatory treatment preserves follicles that would otherwise be permanently lost. For alopecia areata, the FDA approval of JAK inhibitor biologics has created a treatment option that produces substantial regrowth in patients who previously had limited therapeutic recourse. And for telogen effluvium, identifying the systemic or nutritional trigger resolves the shedding and, often, reveals a treatable underlying condition that was otherwise going undetected.

If you are experiencing hair loss of any kind, a professional evaluation provides the specific diagnosis, realistic treatment expectations, and personalized management plan that produces the best possible outcome for your specific type of alopecia. At Connolly Dermatology, our board-certified dermatologists offer expert evaluation with trichoscopy and scalp biopsy when indicated, access to the full spectrum of evidence-based alopecia treatments, and the honest, compassionate communication you deserve when discussing something as personal as your hair.

Schedule a visit with a dermatologist to get clear, informed guidance about your hair loss.